SV2003000925A - Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 - Google Patents
Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7Info
- Publication number
- SV2003000925A SV2003000925A SV2002000925A SV2002000925A SV2003000925A SV 2003000925 A SV2003000925 A SV 2003000925A SV 2002000925 A SV2002000925 A SV 2002000925A SV 2002000925 A SV2002000925 A SV 2002000925A SV 2003000925 A SV2003000925 A SV 2003000925A
- Authority
- SV
- El Salvador
- Prior art keywords
- inhibitors
- spirotricicly
- phosphodiesterase
- derivatives
- new
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 abstract 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
LA INVENCION PROVEE COMPUESTOS QUE SON INHIBIDORES DE PDE7 QUE TIENEN LAS SIGUIENTES FORMULAS (I), (II) Y (III) VER FORMULAS, EN DONDE X1, X2, X3, X4, X5, X Y Z, A Y Z1 SON LO DEFINIDO EN MEMORIA DESCRIPTIVA, METODOS PARA PREPARALOS Y SU USO PARA PREPARAR UNA COMPOSICION FARMACEUTICA DE UTILIDAD PARA EL TRATAMIENTO DE TRASTORNOS PARA LOS CUALES LA TERAPIA CON INHIBIDOR DE PDE7 ES RELEVANTE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2001/003355 WO2002076953A1 (en) | 2001-03-21 | 2001-03-21 | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2003000925A true SV2003000925A (es) | 2003-05-20 |
Family
ID=8164349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2002000925A SV2003000925A (es) | 2001-03-21 | 2002-03-20 | Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 |
Country Status (46)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| GB0230195D0 (en) * | 2002-12-24 | 2003-02-05 | Biofocus Plc | Compound Libraries |
| WO2004096139A2 (en) | 2003-04-24 | 2004-11-11 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| JP2006219373A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| CN1835753A (zh) * | 2003-08-12 | 2006-09-20 | 弗·哈夫曼-拉罗切有限公司 | 作为促皮质释放素(cfr)拮抗剂的螺－取代的四氢喹唑啉 |
| BRPI0512916B1 (pt) | 2004-07-01 | 2020-09-15 | Daiichi Sankyo Company Limited | Derivado de tienopirazol tendo atividade inibidora de pde 7 |
| WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| GB0504209D0 (en) * | 2005-03-01 | 2005-04-06 | Pfizer Ltd | New use of PDE7 inhibitors |
| CA2599662A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of pde7 inhibitors for the treatment of neuropathic pain |
| KR100680497B1 (ko) * | 2005-07-25 | 2007-02-08 | 엘지전자 주식회사 | 근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법 |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| AU2006282896A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8067433B2 (en) | 2005-11-09 | 2011-11-29 | Zalicus Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
| AU2006321349A1 (en) | 2005-12-02 | 2007-06-07 | Pfizer Limited | Spirocyclic quinazoline derivatives as PDE7 inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| CA2662491A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| RU2449790C2 (ru) * | 2007-03-27 | 2012-05-10 | Омерос Корпорейшен | Использование ингибиторов pde7 для лечения нарушений движения |
| EP2160381A2 (en) * | 2007-05-24 | 2010-03-10 | Pfizer Limited | Spirocyclic quinazoline derivatives and their use as pde7 inhibitors |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2012064667A2 (en) | 2010-11-08 | 2012-05-18 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| MX393494B (es) | 2013-04-19 | 2025-03-24 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| DK3395817T3 (da) * | 2015-12-16 | 2022-03-21 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Pyrido[1,2-a]pyrimidonanalog, krystalform deraf, mellemprodukt deraf og fremgangsmåde til fremstilling deraf |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107382976A (zh) * | 2017-07-04 | 2017-11-24 | 孙秀芹 | 一种治疗盆腔炎的化合物及制备方法和应用 |
| JP7213863B2 (ja) * | 2017-07-12 | 2023-01-27 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ７阻害剤としての置換ベンゾオキサゾール及びベンゾフラン化合物 |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4572766A1 (en) | 2022-08-18 | 2025-06-25 | Mitodicure GmbH | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5815979A (ja) | 1981-07-11 | 1983-01-29 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体およびその製造法 |
| US4764512A (en) | 1986-08-27 | 1988-08-16 | Rorer Pharmaceutical Corporation | Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses |
| GR1000821B (el) * | 1988-11-22 | 1993-01-25 | Tanabe Seiyaku Co | Μεθοδος παραγωγης παραγωγων κιναζολινονης. |
| RO115804B1 (ro) | 1992-12-11 | 2000-06-30 | Merck & Co Inc | Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora |
| US5536716A (en) | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
| US5602143A (en) * | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
| AU704133B2 (en) * | 1995-10-17 | 1999-04-15 | Astrazeneca Ab | Pharmaceutically active quinazoline compounds |
| CN1205008A (zh) * | 1996-08-30 | 1999-01-13 | 协和发酵工业株式会社 | 咪唑并喹唑啉衍生物 |
| ES2226833T3 (es) | 1999-05-04 | 2005-04-01 | Wyeth | Composiciones anticonceptivas que contienen agentes antiprogestinicos y progestinicos. |
| US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| WO2000066560A1 (en) * | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| AU2274101A (en) | 1999-12-21 | 2001-07-03 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
-
2001
- 2001-03-21 WO PCT/EP2001/003355 patent/WO2002076953A1/en active Application Filing
- 2001-03-21 AP APAP/P/2003/002857A patent/AP1699A/en active
-
2002
- 2002-03-05 TW TW091104028A patent/TWI267509B/zh not_active IP Right Cessation
- 2002-03-18 KR KR1020037012247A patent/KR100617435B1/ko not_active Expired - Fee Related
- 2002-03-18 DE DE60221233T patent/DE60221233T2/de not_active Expired - Lifetime
- 2002-03-18 SK SK1156-2003A patent/SK11562003A3/sk not_active Application Discontinuation
- 2002-03-18 AT AT02732544T patent/ATE367381T1/de not_active IP Right Cessation
- 2002-03-18 EA EA200300906A patent/EA006815B1/ru unknown
- 2002-03-18 JP JP2002573763A patent/JP4086663B2/ja not_active Expired - Fee Related
- 2002-03-18 TN TNPCT/EP2002/003594A patent/TNSN03076A1/en unknown
- 2002-03-18 EP EP07104642A patent/EP1801106A3/en not_active Withdrawn
- 2002-03-18 PT PT02732544T patent/PT1373224E/pt unknown
- 2002-03-18 GE GE5294A patent/GEP20053631B/en unknown
- 2002-03-18 RS YUP-740/03A patent/RS50429B/sr unknown
- 2002-03-18 CA CA002441313A patent/CA2441313C/en not_active Expired - Fee Related
- 2002-03-18 ES ES02732544T patent/ES2288552T3/es not_active Expired - Lifetime
- 2002-03-18 UA UA2003098601A patent/UA74243C2/uk unknown
- 2002-03-18 NZ NZ527847A patent/NZ527847A/en unknown
- 2002-03-18 CN CNB028069714A patent/CN100447136C/zh not_active Expired - Fee Related
- 2002-03-18 HU HU0303637A patent/HUP0303637A3/hu unknown
- 2002-03-18 OA OA1200300226A patent/OA12454A/en unknown
- 2002-03-18 SI SI200230587T patent/SI1373224T1/sl unknown
- 2002-03-18 EP EP02732544A patent/EP1373224B1/en not_active Expired - Lifetime
- 2002-03-18 AU AU2002304800A patent/AU2002304800B2/en not_active Ceased
- 2002-03-18 MX MXPA03008485A patent/MXPA03008485A/es active IP Right Grant
- 2002-03-18 PL PL02367058A patent/PL367058A1/xx not_active Application Discontinuation
- 2002-03-18 WO PCT/EP2002/003594 patent/WO2002074754A1/en active Application Filing
- 2002-03-18 MY MYPI20020954A patent/MY142045A/en unknown
- 2002-03-18 CZ CZ20032451A patent/CZ20032451A3/cs unknown
- 2002-03-18 DK DK02732544T patent/DK1373224T3/da active
- 2002-03-18 EE EEP200300459A patent/EE200300459A/xx unknown
- 2002-03-18 HR HR20030740A patent/HRP20030740A2/hr not_active Application Discontinuation
- 2002-03-18 IL IL15765902A patent/IL157659A0/xx active IP Right Grant
- 2002-03-18 BR BR0208192-0A patent/BR0208192A/pt not_active IP Right Cessation
- 2002-03-19 US US10/101,996 patent/US20020198198A1/en not_active Abandoned
- 2002-03-20 PA PA20028541601A patent/PA8541601A1/es unknown
- 2002-03-20 GT GT200200053A patent/GT200200053A/es unknown
- 2002-03-20 SV SV2002000925A patent/SV2003000925A/es not_active Application Discontinuation
- 2002-03-20 AR ARP020100993A patent/AR033617A1/es active IP Right Grant
- 2002-03-20 PE PE2002000212A patent/PE20021010A1/es not_active Application Discontinuation
-
2003
- 2003-08-25 ZA ZA200306601A patent/ZA200306601B/en unknown
- 2003-08-27 EC EC2003004750A patent/ECSP034750A/es unknown
- 2003-08-28 IL IL157659A patent/IL157659A/en not_active IP Right Cessation
- 2003-08-29 CU CU20030188A patent/CU23218A3/es not_active IP Right Cessation
- 2003-08-29 IS IS6934A patent/IS2529B/is unknown
- 2003-09-12 MA MA27310A patent/MA27001A1/fr unknown
- 2003-09-17 BG BG108181A patent/BG108181A/xx active Pending
- 2003-09-19 NO NO20034187A patent/NO326086B1/no not_active IP Right Cessation
-
2004
- 2004-05-24 US US10/852,404 patent/US7214676B2/en not_active Expired - Fee Related
-
2006
- 2006-10-20 US US11/551,687 patent/US20070049558A1/en not_active Abandoned
-
2007
- 2007-08-30 CY CY20071101121T patent/CY1106829T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2003000925A (es) | Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 | |
| CR7716A (es) | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor | |
| SV2008001369A (es) | Benzimidazoles | |
| ECSP034774A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
| ECSP034773A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
| CR8102A (es) | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa | |
| HN2001000019A (es) | Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4. | |
| UY30327A1 (es) | Nuevos compuestos ii | |
| HN2003000064A (es) | Derivados de nicotinamida utiles como inhibidores de pde4 | |
| UY28572A1 (es) | Compuestos novedosos | |
| ECSP055671A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa | |
| BRPI0412404A (pt) | uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea | |
| UY28342A1 (es) | Nuevos compuestos | |
| UY31456A1 (es) | Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos | |
| CU23778B7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
| ECSP067076A (es) | Derivados de pirimidina urea como inhibidores de la quinasa | |
| SV2005001979A (es) | "pirido[2,3-d]pirimidina-2,4-diaminas como inhibidores de pde 2 " ref. pc25123a | |
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| HN2001000217A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7 | |
| ECSP066767A (es) | Derivados 1h-tieno[2,3-c]pirazol útiles como inhibidores de quinasa | |
| HN2002000365A (es) | Lactamas como antagonistas de taquiquininas | |
| UY27452A1 (es) | Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer | |
| PA8586801A1 (es) | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso | |
| UY28524A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant | ||
| FD | Lapse |